119 related articles for article (PubMed ID: 38309505)
21. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.
Jones RA; Robinson TJ; Liu JC; Shrestha M; Voisin V; Ju Y; Chung PE; Pellecchia G; Fell VL; Bae S; Muthuswamy L; Datti A; Egan SE; Jiang Z; Leone G; Bader GD; Schimmer A; Zacksenhaus E
J Clin Invest; 2016 Oct; 126(10):3739-3757. PubMed ID: 27571409
[TBL] [Abstract][Full Text] [Related]
22. BRD4 isoforms have distinct roles in tumour progression and metastasis in rhabdomyosarcoma.
Das D; Leung JY; Balamurugan S; Tergaonkar V; Loh AHP; Chiang CM; Taneja R
EMBO Rep; 2024 Feb; 25(2):832-852. PubMed ID: 38191874
[TBL] [Abstract][Full Text] [Related]
23. Demethylase-independent function of JMJD2D as a novel antagonist of p53 to promote Liver Cancer initiation and progression.
Li M; Deng Y; Zhuo M; Zhou H; Kong X; Xia X; Su Z; Chen Q; Guo P; Mo P; Yu C; Li W
Theranostics; 2020; 10(19):8863-8879. PubMed ID: 32754284
[No Abstract] [Full Text] [Related]
24. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
[TBL] [Abstract][Full Text] [Related]
25. Targeting USP1-dependent KDM4A protein stability as a potential prostate cancer therapy.
Cui SZ; Lei ZY; Guan TP; Fan LL; Li YQ; Geng XY; Fu DX; Jiang HW; Xu SH
Cancer Sci; 2020 May; 111(5):1567-1581. PubMed ID: 32133742
[TBL] [Abstract][Full Text] [Related]
26. Brd4-bound enhancers drive cell-intrinsic sex differences in glioblastoma.
Kfoury N; Qi Z; Prager BC; Wilkinson MN; Broestl L; Berrett KC; Moudgil A; Sankararaman S; Chen X; Gertz J; Rich JN; Mitra RD; Rubin JB
Proc Natl Acad Sci U S A; 2021 Apr; 118(16):. PubMed ID: 33850013
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic regulation of asymmetric cell division by the LIBR-BRD4 axis.
Chen HF; Chang CT; Hsu KW; Peng PH; Lai JC; Hung MC; Wu KJ
Nucleic Acids Res; 2024 Jan; 52(1):154-165. PubMed ID: 37986225
[TBL] [Abstract][Full Text] [Related]
28. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
29. CRISPR/Cas9-based genome-wide screening for deubiquitinase subfamily identifies USP1 regulating MAST1-driven cisplatin-resistance in cancer cells.
Tyagi A; Kaushal K; Chandrasekaran AP; Sarodaya N; Das S; Park CH; Hong SH; Kim KS; Ramakrishna S
Theranostics; 2022; 12(13):5949-5970. PubMed ID: 35966591
[No Abstract] [Full Text] [Related]
30. DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4.
Jin X; Yan Y; Wang D; Ding D; Ma T; Ye Z; Jimenez R; Wang L; Wu H; Huang H
Mol Cell; 2018 Aug; 71(4):592-605.e4. PubMed ID: 30057199
[TBL] [Abstract][Full Text] [Related]
31. MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53.
Hines J; Lartigue S; Dong H; Qian Y; Crews CM
Cancer Res; 2019 Jan; 79(1):251-262. PubMed ID: 30385614
[TBL] [Abstract][Full Text] [Related]
32. IGFBP-rP1 induces p21 expression through a p53-independent pathway, leading to cellular senescence of MCF-7 breast cancer cells.
Zuo S; Liu C; Wang J; Wang F; Xu W; Cui S; Yuan L; Chen X; Fan W; Cui M; Song G
J Cancer Res Clin Oncol; 2012 Jun; 138(6):1045-55. PubMed ID: 22392074
[TBL] [Abstract][Full Text] [Related]
33. Inducible STAT3 NH2 terminal mono-ubiquitination promotes BRD4 complex formation to regulate apoptosis.
Ray S; Zhao Y; Jamaluddin M; Edeh CB; Lee C; Brasier AR
Cell Signal; 2014 Jul; 26(7):1445-55. PubMed ID: 24657799
[TBL] [Abstract][Full Text] [Related]
34. Functional interplay between p53 and E2F through co-activator p300.
Lee CW; Sørensen TS; Shikama N; La Thangue NB
Oncogene; 1998 May; 16(21):2695-710. PubMed ID: 9652736
[TBL] [Abstract][Full Text] [Related]
35. The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer.
Pang Y; Bai G; Zhao J; Wei X; Li R; Li J; Hu S; Peng L; Liu P; Mao H
J Transl Med; 2022 Jul; 20(1):336. PubMed ID: 35902869
[TBL] [Abstract][Full Text] [Related]
36. Ubiquitin-specific protease 1 acts as an oncogene and promotes lenvatinib efficacy in hepatocellular carcinoma by stabilizing c-kit.
Chen Z; Ma Y; Guo Z; Song D; Chen Z; Sun M
Ann Hepatol; 2022; 27(2):100669. PubMed ID: 35045360
[TBL] [Abstract][Full Text] [Related]
37. HistoneH3 demethylase JMJD2A promotes growth of liver cancer cells through up-regulating miR372.
An J; Xu J; Li J; Jia S; Li X; Lu Y; Yang Y; Lin Z; Xin X; Wu M; Zheng Q; Pu H; Gui X; Li T; Lu D
Oncotarget; 2017 Jul; 8(30):49093-49109. PubMed ID: 28467776
[TBL] [Abstract][Full Text] [Related]
38. Aberrant Activation of β-Catenin Signaling Drives Glioma Tumorigenesis via USP1-Mediated Stabilization of EZH2.
Ma L; Lin K; Chang G; Chen Y; Yue C; Guo Q; Zhang S; Jia Z; Huang TT; Zhou A; Huang S
Cancer Res; 2019 Jan; 79(1):72-85. PubMed ID: 30425057
[TBL] [Abstract][Full Text] [Related]
39. KDM6A-Mediated Expression of the Long Noncoding RNA DINO Causes TP53 Tumor Suppressor Stabilization in Human Papillomavirus 16 E7-Expressing Cells.
Sharma S; Munger K
J Virol; 2020 Jun; 94(12):. PubMed ID: 32269126
[TBL] [Abstract][Full Text] [Related]
40. Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells.
Mistry H; Hsieh G; Buhrlage SJ; Huang M; Park E; Cuny GD; Galinsky I; Stone RM; Gray NS; D'Andrea AD; Parmar K
Mol Cancer Ther; 2013 Dec; 12(12):2651-62. PubMed ID: 24130053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]